These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8152328)

  • 21. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
    Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
    Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary metabolites of p-hydroxyamphetamine in man, rat and guinea-pig.
    Sever PS; Dring LG; Williams RT
    Xenobiotica; 1976 Jun; 6(6):345-53. PubMed ID: 969562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 isozymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes.
    Suzuki T; Fujita S; Narimatsu S; Masubuchi Y; Tachibana M; Ohta S; Hirobe M
    FASEB J; 1992 Jan; 6(2):771-6. PubMed ID: 1537468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amphetamine, p-hydroxyamphetamine and beta-phenethylamine in mouse brain and urine after (-)- and (+)-deprenyl administration.
    Philips SR
    J Pharm Pharmacol; 1981 Nov; 33(11):739-41. PubMed ID: 6118419
    [No Abstract]   [Full Text] [Related]  

  • 25. Blood pressure and heart rate response evoked by p-hydroxyamphetamine and by p-hydroxynorephedrine II. A quantitative assessment of the role of amphetamine metabolites in acute responses evoked by d-amphetamine.
    Simpson LL
    J Pharmacol Exp Ther; 1980 Jun; 213(3):504-8. PubMed ID: 7205614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of dark agouti rats.
    Suzuki T; Narimatsu S; Fujita S; Masubuchi Y; Umeda S
    Biochem Pharmacol; 1991 Nov; 42(11):2241-4. PubMed ID: 1958240
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of amphetamine metabolism using isolated hepatocytes from five species including human.
    Green CE; LeValley SE; Tyson CA
    J Pharmacol Exp Ther; 1986 Jun; 237(3):931-6. PubMed ID: 3712286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
    Colado MI; Williams JL; Green AR
    Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic differences in spatial learning between Dark Agouti and Sprague-Dawley strains: possible correlation with the CYP2D2 polymorphism in rats treated neonatally with methamphetamine.
    Vorhees CV; Morford LL; Inman SL; Reed TM; Schilling MA; Cappon GD; Moran MS; Nebert DW
    Pharmacogenetics; 1999 Apr; 9(2):171-81. PubMed ID: 10376764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formation of alpha-methyldopamine ("Catecholamphetamine") from p-hydroxyamphetamine by rat brain microsomes.
    Hoffman AR; Sastry BV; Axelrod J
    Pharmacology; 1979; 19(5):256-60. PubMed ID: 538080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strain differences in CYP3A-mediated C-8 hydroxylation (1,3,7-trimethyluric acid formation) of caffeine in Wistar and Dark Agouti rats. Rapid metabolism of caffeine in debrisoquine poor metabolizer model rats.
    Morita K; Maeda Y; Masuda M; Kazusaka A; Imaoka S; Funae Y; Fujita S
    Biochem Pharmacol; 1998 May; 55(9):1405-11. PubMed ID: 10076532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark Agouti rat model.
    Cleary J; Mikus G; Somogyi A; Bochner F
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1528-34. PubMed ID: 7996467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biliary excretion of amphetamine and methamphetamine in the rat.
    Caldwell J; Dring LG; Williams RT
    Biochem J; 1972 Aug; 129(1):25-9. PubMed ID: 4646778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition kinetics of d- and l-amphetamine following intravenous administration of racemic amphetamine to rats.
    Hutchaleelaha A; Sukbuntherng J; Chow HH; Mayersohn M
    Drug Metab Dispos; 1994; 22(3):406-11. PubMed ID: 8070317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6.
    Laurenzana EM; Sorrels SL; Owens SM
    Drug Metab Dispos; 1995 Feb; 23(2):271-8. PubMed ID: 7736924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytochrome P450-dependent disposition of the enantiomers of citalopram and its metabolites: in vivo studies in Sprague-Dawley and Dark Agouti rats.
    Kingbäck M; Carlsson B; Ahlner J; Bengtsson F; Kugelberg FC
    Chirality; 2011 Feb; 23(2):172-7. PubMed ID: 20848647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous HPLC analysis of optical isomers of methamphetamine and its metabolites, and stereoselective metabolism of racemic methamphetamine in rat urine.
    Nagai T; Kamiyama S
    J Anal Toxicol; 1991; 15(6):299-304. PubMed ID: 1685757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The contribution of the metabolite p-hydroxyamphetamine to the central actions of p-methoxyamphetamine.
    Kaminskas LM; Irvine RJ; Callaghan PD; White JM; Kirkbride P
    Psychopharmacology (Berl); 2002 Mar; 160(2):155-60. PubMed ID: 11875633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hydroxylation of debrisoquine using perfused liver isolated from Sprague Dawley and DA rats: comparison with in-vivo results.
    Vincent-Viry M; Deshayes S; Mothe O; Siest G; Galteau MM
    J Pharm Pharmacol; 1988 Oct; 40(10):695-700. PubMed ID: 2907535
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.
    Larrey D; Distlerath LM; Dannan GA; Wilkinson GR; Guengerich FP
    Biochemistry; 1984 Jun; 23(12):2787-95. PubMed ID: 6432035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.